Omeros Corporation Total Liabilities
Omeros Corporation total liabilities. Based on the latest financial reports, Omeros Corporation (OMER) has total liabilities worth $338.18 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check OMER cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Omeros Corporation (2007–2025)
Total liabilities of Omeros Corporation from 2007 to 2025. This chart illustrates how Omeros Corporation's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of Omeros Corporation to see how much of total assets are deployed in long-term investments.
Omeros Corporation Competitors by Total Liabilities
The table below lists competitors of Omeros Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Trident Limited
NSE:TRIDENT
|
India | Rs26.00 Billion |
|
WEBTOON Entertainment Inc. Common stock
NASDAQ:WBTN
|
USA | $368.64 Million |
|
Ocean’s King Lighting Science & Technology Co Ltd
SHE:002724
|
China | CN¥627.08 Million |
|
Dole PLC
NYSE:DOLE
|
USA | $2.93 Billion |
|
Ennostar Inc
TW:3714
|
Taiwan | NT$9.23 Billion |
|
Eaglerise Electric & Electronic China Co Ltd Class A
SHE:002922
|
China | CN¥5.64 Billion |
|
Xiamen Meiya Pico Information
SHE:300188
|
China | CN¥1.79 Billion |
|
Manorama Industries Limited
NSE:MANORAMA
|
India | Rs-6.82 Billion |
Liability Composition Analysis (2007–2025)
This chart breaks down Omeros Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Omeros Corporation asset portfolio.
Liquidity & Leverage Metrics
Omeros Corporation Total Liabilities Ratios Explained
Omeros Corporation total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -6.59 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Omeros Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Omeros Corporation (2007–2025)
The table below shows the annual total liabilities of Omeros Corporation from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $446.86 Million | -2.79% |
| 2024-12-31 | $459.69 Million | +14.00% |
| 2023-12-31 | $403.25 Million | -20.19% |
| 2022-12-31 | $505.29 Million | +27.76% |
| 2021-12-31 | $395.49 Million | +31.05% |
| 2020-12-31 | $301.79 Million | +22.69% |
| 2019-12-31 | $245.99 Million | -5929.15% |
| 2018-12-31 | $-4.22 Million | -103.54% |
| 2017-12-31 | $119.14 Million | +13.77% |
| 2016-12-31 | $104.72 Million | +39.21% |
| 2015-12-31 | $75.23 Million | +39.98% |
| 2014-12-31 | $53.74 Million | +53.91% |
| 2013-12-31 | $34.92 Million | -85.52% |
| 2012-12-31 | $241.15 Million | +641.19% |
| 2011-12-31 | $32.54 Million | +28.94% |
| 2010-12-31 | $25.23 Million | +33.39% |
| 2009-12-31 | $18.92 Million | -83.24% |
| 2008-12-31 | $112.85 Million | +16.21% |
| 2007-12-31 | $97.10 Million | -- |
About Omeros Corporation
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinic… Read more